Cellectis (NASDAQ:CLLS) Share Price Crosses Below 50-Day Moving Average – Here’s What Happened
by Doug Wharley · The Cerbat GemCellectis S.A. (NASDAQ:CLLS – Get Free Report)’s share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.50 and traded as low as $2.79. Cellectis shares last traded at $2.94, with a volume of 21,957 shares.
Analysts Set New Price Targets
CLLS has been the subject of a number of analyst reports. Barclays started coverage on shares of Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target for the company. Citizens Jmp reissued a “market outperform” rating and set a $8.00 price objective on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.
View Our Latest Report on CLLS
Cellectis Price Performance
The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $295.00 million, a P/E ratio of -4.39 and a beta of 2.86. The stock has a 50 day moving average of $3.48 and a 200-day moving average of $3.79.
Cellectis (NASDAQ:CLLS – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.08. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.04 million.
Institutional Investors Weigh In On Cellectis
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Global Retirement Partners LLC purchased a new stake in Cellectis in the 4th quarter valued at about $34,000. Lido Advisors LLC purchased a new position in shares of Cellectis during the first quarter worth approximately $32,000. Millennium Management LLC increased its position in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares during the period. B Group Inc. raised its stake in shares of Cellectis by 0.8% during the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock valued at $9,352,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Cellectis during the third quarter valued at approximately $72,000. Institutional investors own 63.90% of the company’s stock.
About Cellectis
Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.
The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.